Skip to content

RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%

Chronic dry eye is a medical condition that can result from the eyes’ reduced ability to produce tears due to inflammation. Dry eye affects an estimated 25 million people in the United States1 and is one of the most common reasons that people visit their eye care professional.

Artificial tears are over the counter products that can provide temporary relief from dry eye. RESTASIS®, approved by the U.S. Food and Drug Administration in 2002, is the first and currently the only prescription medicine that helps to increase your eyes' natural ability to produce tears which may be reduced by inflammation due to chronic dry eye. RESTASIS® ophthalmic emulsion did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.

Approved Use

RESTASIS® Ophthalmic Emulsion helps increase your eyes’ natural ability to produce tears, which may be reduced by inflammation due to Chronic Dry Eye. RESTASIS® did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.

Important Safety Information

Do not use RESTASIS® Ophthalmic Emulsion if you are allergic to any of the ingredients. To help avoid eye injury and contamination, do not touch the vial tip to your eye or other surfaces. RESTASIS® should not be used while wearing contact lenses. If contact lenses are worn, they should be removed prior to the use.

The most common side effect is a temporary burning sensation. Other side effects include eye redness, discharge, watery eyes, eye pain, foreign body sensation, itching, stinging, and blurred vision.

Please click here for full RESTASIS® Prescribing Information (PDF) 
RESTASIS® Web site 


APC84JP13




  1. Market Scope. 2011 Comprehensive Report on the Global Dry Eye Products Market. St. Louis, Mo: Market Scope, November 2011, page 52.